NCT02473016已完成2 期
A Placebo-Controlled, Single-Blind Study Evaluating the Safety and Efficacy of Nasal Carbon Dioxide for the Symptomatic Treatment of Classical Trigeminal Neuralgia
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Capnia, Inc.
- 入组人数
- 30
- 试验地点
- 6
- 主要终点
- Pain relief assessed on a visual analog scale (VAS) in a subject diary
研究概览
简要总结
A placebo-controlled, single-blind study to evaluate the safety and preliminary efficacy of nasal carbon dioxide for the symptomatic treatment of classical trigeminal neuralgia.
研究设计
- 研究类型
- Interventional
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female, 18 years of age and older.
- •History of classical trigeminal neuralgia with or without persistent background facial pain, not secondary, as defined by International Classification of Headache Disorders (ICHD), third edition, beta version (ICHD-3 beta, Cephalalgia 2013).
- •Diagnosis of trigeminal neuralgia (TN) for at least 60 days prior to enrollment.
- •Experience pain with a score of at least 5 on a 0-10 scale during a typical TN episode as reported by subject. Note: Prior to treatment pain score must a 5 or greater on a VAS.
- •History of unilateral typical TN pain predominantly in the V2 branch of the trigeminal nerve.
- •Absence of a significant structural lesion (e.g., a tumor) as the cause of pain as shown in at least one neuro-imaging study.
- •On stable dose of all medications, including those for the treatment of TN prevention/prophylaxis, for at least 14 days prior to baseline (including, but not limited to, verapamil, lithium, melatonin, any anticonvulsant, any systemic corticosteroid or steroid injection, occipital nerve block, other cranial or extracranial nerve block, or any neurostimulation treatment). Note: Subjects are allowed to use their usual standard of care for the acute/abortive treatment of trigeminal neuralgia attacks 60 or more minutes after the initial dose, provided it is approved by the investigator.
- •Capable of completing a diary.
- •Able to provide written Informed Consent.
排除标准
- •Are unable to comply with protocol requirements.
- •Have recent of alcohol or drug abuse within 2 years prior to study enrollment.
- •Current major psychiatric disorder: suicidal ideation, bipolar, panic disorder, schizophrenic, or psychosis. Subjects who are documented as clinically stable and not exhibiting symptoms related to their psychiatric disorder are eligible.
- •History of asthma (other than mild or intermittent).
- •Have an existing serious unstable systemic disease (e.g., severe emphysema, other respiratory diseases, heart disease, etc.) that precludes participation.
- •Clinically significant nasal disorder (deviated septum, presence of polyps, evidence of significant congestion, rhinitis, or other nasal abnormalities) that prevents unrestricted breathing through each nostril.
- •Currently on anticoagulants or have a diagnosis of a bleeding disorder.
- •Current diagnosis of fibromyalgia, temporomandibular disorders (TMD), odontogenic pain or other orofacial pain.
- •Surgery for treatment of TN within 30 days prior to screening. Note: Investigator must ensure that patients who have had surgery have recovered and are not experiencing any side effects from surgery for treatment of TN
- •Females who are pregnant or breast-feeding and/or plan to become pregnant or to breast-feed during study participation or within 30 days after treatment.
- •Participation in a previous study with nasal CO
- •Participation in another investigational drug study within 30 days prior to randomization.
研究组 & 干预措施
Treatment
Experimental
All subjects will receive both Active (Carbon Dioxide Drug Delivery System) and Placebo. This is a single-blind study so subjects will not know the order. Subjects will receive 3 doses of active and 3 doses of placebo. One dose is a 60 second delivery of CO2 or placebo. At the discretion of the investigator, subjects may receive up to 3 additional doses of CO2.
干预措施: Carbon Dioxide Drug Delivery System (CDDS) (Drug)
结局指标
主要结局
Pain relief assessed on a visual analog scale (VAS) in a subject diary
时间窗: Assessed through 24 hours from initial dose
次要结局
- Percentage of subjects experiencing pain freedom at 5-60 minutes assessed on a visual analog scale (VAS) in a subject diary(Assessed through 60 minutes post intial dose)
- Reduction in the number of attacks (recorded in a subject diary)(Assessed through 24 hours from initial dose)
- Increase in duration between episodes of pain (recorded in a subject diary)(Assessed through 24 hours from initial dose)
- Percentage of subjects with pain relief 5-60 minutes assessed on a visual analog scale (VAS) in a subject diary(Assessed through 60 minutes post intial dose)
- Rescue medication usage (recorded in a subject diary)(Assessed through 24 hours from initial dose)
- Subject satisfaction (recorded in a subject diary)(Assessed through 24 hours from initial dose)
- Attack recurrence (recorded in a subject diary)(Assessed through 24 hours from initial dose)
- Decreased trigger sensitivity (recorded in a subject diary)(Assessed through 24 hours from initial dose)
- Reported Adverse Events (recorded in a subject diary and during follow up phone calls)(Up to 7 days after inital dose)
- Reduction in intensity of attacks (recorded in a subject diary)(Assessed through 24 hours from initial dose)
研究者
研究点 (6)
Loading locations...
相似试验
已完成
3 期
Study In Adults And Adolescents With Seasonal Allergic RhinitisHayfeverRhinitis, Allergic, SeasonalSeasonal Allergic RhinitisNCT00115622GlaxoSmithKline304
已完成
2 期
A Pilot Study In Adults And Adolescents With Irritant (Non-Allergic) RhinitisRhinitis, Allergic, PerennialNCT00730756GlaxoSmithKline102
已完成
3 期
Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR)Seasonal Allergic RhinitisHay FeverNCT01024608Teva Branded Pharmaceutical Products R&D, Inc.340
已完成
3 期
Study In Adults And Adolescents With Seasonal Allergic Rhinitis.Rhinitis, Allergic, SeasonalNCT00225823GlaxoSmithKline288
已完成
4 期
A randomized controlled trial using nasal cannula to decrease hypoxia in pediatric patient during rapid sequence intubation compared with control groupHealthy neonates, infants, and children aged up to 6 years old.Scheduled for elective or emergency surgery under general anesthesia with rapid sequence induction and intubation.rapid sequence induction and intubationapnea oxygenationneonates, infants, and childrennasal cannulaTCTR20210802002Siriraj Research Development Fund, Faculty of Medicine, Siriraj Hospital,Mahidol University64